reports
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, P...
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quar...
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, ...
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering opportunities for the hunTR® platform as well as broad strategic alternativesReducing headcount by approximately 60% while retaining key hunTR® R&D capabilities HOUS...
Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global S...
Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023. Alaunos Director of Translational Sciences Matthew Collinson-Pautz, Ph.D., will discuss the Company’s TCR-T therapy...
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/...
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indicationsTreatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in peripheral blood observed in all three treated patients at last follow-upProof-of-concept demonstrated for non-viral Sleeping Beauty cell engineering platform in effective manufa...
Alaunos Therapeutics Reports First Quarter 2023 Financial Results
Alaunos Therapeutics Reports First Quarter 2023 Financial Results Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley Bank; now a debt-free companyAmended exclusive licensing agreement with Precigen, Inc., reflecting the Company’s focus on its TCR-T programs and eliminating long-term financial obligationsCompany to host conference call today at 9:00 a.m. ET HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” o...
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on...
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the finan...
Alaunos Therapeutics Announces Poster Presentation at the American Soc...
Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster presentation for its lead non-viral Sleeping Beauty TCR-T cell therapy program in solid tumors at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, at the McCor...
Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Dir...
Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors Industry leader brings more than 25 years of scientific leadership and expertise in T-cell therapy development HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company’s Board of D...
Alaunos Therapeutics to Participate in Upcoming Investor Conferences i...
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences. Cantor's The Future of Oncology Virtual SymposiumDate: Tuesday, April 4, 2023 Format: Fireside Chat and 1x1 MeetingsLocation: Virtual 22nd Annual Needham Virtual Heal...
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financi...
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides support for next generation TCR-T effortsAdvancing TCR-T Library Program towards Phase 2 readiness with accelerated patient enrollment following proof-of-concept of Sleeping Beauty TCR-T in solid tumors targeting driver mutationsExpanded TCR library with two new TCRs; expect to increase to 15 TCRs using hunTR® TCR discovery platform in 2023Executing against...
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Finan...
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023 HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on Tuesday, March 7, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to review the financial results and provide a corpor...
Alaunos Therapeutics Highlights Strategic Priorities and Anticipated P...
Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023 Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platformIncreasing patient enrollment to advance TCR-T Library Program towards Phase 2 using high value TCRs targeting common hotspot mutations in six solid tumor indicationsExecuting against multi-pronged strategy to expand and optimize manufacturing capabilities and processes towards commercial scalabilityAdvancing our mbIL-15 program ...
Alaunos Therapeutics Announces Pricing of Public Offering of Common St...
Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the pricing of its underwritten public offering of approximately 24,228,719 shares of its common stock for gross proceeds of approximately $15.7 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Alaunos. All of the shares of common stock are being offered by Alaunos...
Alaunos Therapeutics Announces Proposed Public Offering of Common Stoc...
Alaunos Therapeutics Announces Proposed Public Offering of Common Stock HOUSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Alaunos expects to grant to the underwriter a 30-day option to purchase up to an additional 15% of shares of the common stock sold in the public offering. All of the securities in the offering are to be sold by Alaunos. The offering is subject to m...
Alaunos Therapeutics Reports Third Quarter 2022 Financial Results
Alaunos Therapeutics Reports Third Quarter 2022 Financial Results Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON)Actively enrolling patients in TCR-T Library Phase 1/2 trial at the second dose level; expect to treat next patient in 4Q22Expanded manufacturing capacity to produce two products simultaneouslyExpect to file Investigational New Drug (IND) amendment in 4Q22 to add two additional TCRs to TCR library and mo...
Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on...
Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022 HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results. Register for the live webcast using the link or by visiting the “...
Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Disco...
Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting Data supports high-throughput screening process to identify neoantigen-reactive TCRsExclusive ownership of discovered KRAS mutation-reactive TCRshunTR enables expansion of the Company’s hotspot mutation targeted TCR library HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a poster presentation highlighting th...
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Tria...
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post infusionSleeping Beauty TCR-T cell therapy had a manageable safety profile with no dose limiting toxicities observedData to be presented on Friday, September 30 at 9:00am ET in a proffered presentation at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference HOUSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) ...
Alaunos Therapeutics to Participate in Upcoming Investor Conferences i...
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will be participating in the following upcoming investor conferences. 2022 Wells Fargo Healthcare Conference Date: Thursday, September 8, 2022 Format: 1x1 Meetings onlyLocation: Boston, MA Morgan Stanley 20th Annual...
Alaunos Therapeutics Announces Early Clinical Data Showing Objective C...
Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy First patient dosed achieved a confirmed objective partial response Second patient dosed at second dose level; cleared 28-day safety windowData to be presented on Friday, September 30 at 8:30am ET in a proffered presentation at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.